# The association between rs6859 in *NECTIN2* gene and Alzheimer's disease is partly mediated by pTau

-3 4

5

8

9

Running Title: pTau connects NECTIN2 and Alzheimer's disease

Aravind Lathika Rajendrakumar<sup>1\*</sup>, Konstantin G. Arbeev<sup>1</sup>, Olivia Bagley<sup>1</sup>, Anatoliy I. Yashin<sup>1</sup>, Svetlana
 Ukraintseva<sup>1\*</sup>

<sup>1</sup>Biodemography of Aging Research Unit, Duke University, Social Science Research Institute, Durham, NC, USA.

- 10 11
- 12 Word count: 6,113
- 13 Number of tables and figures: 8
- 14
- 15 16 Abstract
- 17

# 18 Introduction

Emerging evidence suggests a connection between vulnerability to infections and Alzheimer's disease (AD). The nectin cell adhesion molecule 2 (*NECTIN2*) gene coding for a membrane component of adherens junctions is involved in response to infection, and its single nucleotide polymorphism (SNP) rs6859 was significantly associated with AD risk in several human cohorts. It is unclear, however, how exactly rs6859 influences the development of AD pathology. The aggregation of hyperphosphorylated tau protein (pTau) is a key pathological feature of neurodegeneration in AD, which may be induced by infections, among other factors, and potentially influenced by genes involved in both AD and vulnerability to infections, such as *NECTIN2*.

26

## 27 Materials and methods

We conducted a causal mediation analysis (CMA) on a sample of 708 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI). The relationship between rs6859 and Alzheimer's disease (AD), with AD

- Neuroimaging Initiative (ADNI). The relationship between rs6859 and Alzheimer's disease (AD), with AD (ves/no) as the outcome and pTau-181 levels in the cerebrospinal fluid (CSF) acting as a mediator in this
- association, was assessed. Adjusted estimates from the probit and linear regression models were used in the
- CMA model, where an additive model considered an increase in dosage of the rs6859 A allele (AD risk factor).

#### 33 **Results**

34 The increase in dose of allele A of the SNP rs6859 resulted in about 0.144 increase per standard deviation (SD)

of pTau-181 (95% CI: 0.041, 0.248, p<0.01). When included together in the probit model, the change in A

- 36 allele dose and each standard deviation change in pTau-181 predicted 6.84% and 9.79% higher probabilities for 37 AD, respectively. In the CMA, the proportion of the average mediated effect was 17.05% and was higher for
- AD, respectively. In the CMA, the proportion of the average mediated effect was 17.05% and was higher for the risk allele homozygotes (AA), at 19.40% (95% CI: 6.20%, 43.00%, p<0.01). The sensitivity analysis
- 39 confirmed the evidence of a robust mediation effect.

# 4041 Conclusion

This study reported a new causal relationship between pTau-181 and AD. We found that the association between rs6859 in the *NECTIN2* gene and AD is partly mediated by pTau-181 levels in CSF. The rest of this association may be mediated by other factors. Further research, using other biomarkers, is needed to uncover the remaining mechanisms of the association between the *NECTIN2* gene and AD.

46

# 47 Keywords

48 Alzheimer's Disease, *NECTIN2* gene, rs6859, pTau-181, causal mediation

49 50			
51			
52			
53			

#### 54 1 Introduction

55 Alzheimer's disease (AD) is a debilitating neurodegenerative disorder that causes severe cognitive impairment (Filho et al., 2017). Identification of biomarkers that accurately reflect pathological changes in the brain is 56 57 critical for AD prediction and treatment (Cox et al., 2022). Protein modification known as 58 hyperphosphorylation of Tau proteins (pTau) contributes to neurofibrillary tangles, a central feature of 59 Alzheimer's pathology (**Drummond et al., 2020**). The pTau concentrations were also linked to amyloid- $\beta$ , another main AD biomarker, in a dose-response manner (Hirota et al., 2022). The utility of pTau as a sensitive 60 61 marker of AD has been well demonstrated (Moore, Hung, and Fortin 2023). Some studies also suggested that 62 the aggregation of pTau may be induced by infections, among other factors (Lee et al., 2022; Sathler et al., 63 2022; Shen et al., 2022; Tang et al., 2022). The involvement of infections in AD is an emerging field of AD 64 research, and the literature on the factors that may influence both vulnerability to infections and 65 neurodegeneration is increasing (Yashin et al., 2018; Yong et al., 2021; Cairns, Itzhaki and Kaplan, 2022; 66 Mancuso et al., 2022; Nuovo et al., 2022; Piekut et al., 2022; Sathler et al., 2022; Tang et al., 2022; Goldhardt et al., 2023; Ukraintseva et al., 2023; Popov et al., 2024). Nectin-2 (Nectin cell adhesion 67 68 molecule 2) is a membrane component of adherens junctions that serves as an entry point for certain 69 herpesviruses and may mediate response to the viral infection (Ogawa et al., 2022; Goldhardt et al., 2023). 70 The single nucleotide polymorphism (SNP) rs6859 of the NECTIN2 gene was highly significantly associated with AD risk in observational human data (Yashin et al., 2018; Mizutani et al., 2022). However, it is unclear 71 how exactly rs6859 facilitates the development of AD pathology. It is unlikely to be through the effects of 72 73 APOE4 (located nearby, on the same chromosome 19), because rs6859 is not in the linkage disequilibrium with 74 APOE4. It is possible that the NECTIN2 polymorphism contributes to AD through its involvement in 75 vulnerability to infections. Since pTau levels can be influenced by infections and related factors, we 76 hypothesized that they may also be influenced by the NECTIN2 gene, involved in both AD and vulnerability to 77 infections, and could mediate the association of this gene with AD.

78

In this paper, we performed causal mediation analysis (CMA) to explore causal relationships among the rs6859
 polymorphism in the *NECTIN2* gene, pTau, and AD using the Alzheimer's Disease Neuroimaging Initiative
 (ADNI) data.

#### 83 2 Materials and methods

84

82

#### 85 2.1 Data

86 We used the UPENNBIOMK Master dataset publicly available from the ADNI consortium upon request 87 (adni.loni.usc.edu). ADNI is an ongoing research study envisaged under Michael W. Weiner with the original aim of generating data from multiple biomarkers, along with clinical and other cognitive assessments, to learn 88 89 about mild cognitive impairment (MCI) and its conversion to full-blown AD in US older adults. The minimum 90 age of recruitment was 55 years, and the study tracks individuals with AD, cognitively normal, and milder 91 cognitive deficits across time (Weiner et al., 2017). The database currently contains comprehensive 92 measurements of various biomarkers, genetic variation, brain volume and structure, and cognitive status 93 (Weiner et al., 2010). The ADNI was conducted in 3 waves: ADNI 1, ADNI GO, ADNI 2, and ADNI 3. For 94 these phases, different genotyping platforms were used for genome-wide association studies (GWAS). These 95 were Illumina Human610-Quad BeadChip, Illumina HumanOmniExpress BeadChip, and Illumina Infinium 96 Global Screening Array v2 (GSA2), respectively, for ADNI waves 1-3. Biomarkers and cognitive 97 measurements were collected during the baseline and subsequent visits. The recorded number of visits ranged 98 from a single visit to a maximum of seven visits per participant. The ADNI data contain individual 99 measurements of pTau-181 levels in the cerebrospinal fluid (CSF) extracted using lumbar puncture and quantified by the fully automated mid-region Roche Elecsys electrochemiluminescence immunoassays 100 101 platform. This pTau181 measure is considered a reference assay for comparing the performance of new pTau 102 epitopes in differentiating AD progression (Suárez Calvet et al., 2020). We extracted the pTau-181 103 information with the corresponding subject ID (RID) and sample draw date and linked the files with age and 104 other demographical information from the demography file. The genotypes of SNP rs6859 were extracted from 105 the Plink binary files using the --recode command from the Plink 1.90 beta version (Purcell and Chang, 2023.; 106 Chang et al., 2015). The SNP information file was used to cross-check the genotype coding. We used the 107 ADNIMERGE file to determine the case and control status for AD.

#### 110

#### 111 **2.2 The Causal Mediation Analysis (CMA)**

112 In this analysis, we hypothesized that the effect of the NECTIN2 polymorphism, represented by the SNP

113 rs6859, on AD is mediated through the pTau levels measured in the CSF. The CMA is a common method for 114 dissecting the total effect of treatment into direct and indirect effects (Nguyen, Schmid and Stuart, 2020). The 115 indirect effect is transmitted via a mediator to the outcome (Figure illustrating the CMA approach in the 116 supplement). The CMA will allow us to see if, and to what degree, the rs6859 could indirectly facilitate AD 117 occurrence through the pTau. In other words, what part of the association between rs6859 and AD could be 118 explained by the causal connection between pTau and AD.

119 Assessment of rs6859, pTau-181, and AD relationship

In this CMA, the relationship between rs6859 and AD, with AD (yes/no) as the outcome, and pTau-181 levels (pg/mL) in the cerebrospinal fluid (CSF) acting as a mediator in this association, was assessed. The pTau-181 was a reasonable choice as a mediator variable for our CMA also because it allowed discrimination between pathology-confirmed AD and other dementia subtypes (Grothe et al., 2021). Information on AD status (yes/no) was an outcome. The control group included both cognitively normal individuals and subjects with dementia, but not AD.

#### 126 Statistical Analysis

127

We used R software version 4.0.0 (Vienna, Austria) to perform the analysis (R Core Team 2021). ggplot2 and 128 129 MuMin packages were used for creating plots and regression model selection, respectively (Wickham, 2016; **Barton**, 2013). Continuous variables with a normal distribution were summarized as mean  $\pm$  standard deviation 130 131 (SD) or median and interquartile range (IQR) for visually skewed distributions. For the causal mediation effects analysis, an additive effect of the increasing dose of allele A of the SNP rs6859 was considered in the model. 132 133 For participants, different concentrations of pTau-181 were recorded during the same visit. To quantify the variation for pTau-181, we calculated the overall median CV% change for the sample and the coefficient of 134 variation percentage (CV%) for repeat measures from the same day, along with their bootstrapped confidence 135 136 intervals (CI). For the corresponding measures, CV% was calculated by dividing the standard deviation by the mean and then multiplying by 100. We did not employ a pass/fail criterion for the inclusion of values, as the 137 138 variations could be biologically relevant, and pruning the data could remove important information. To understand these variations, boxplots were created for daily CV% variations across categorical variables. The 139 140 pTau-181 was summarized to a single reading per participant (median value) to obtain a more stable measure and take advantage of multiple measures, pTau-181 was standardized, i.e., scaled and centred for regression and 141 142 mediation analyses. Age was computed from the final pTau-181 sample draw date and the birth date.

143

Separate regression models were fit to assess the association between pTau-181, rs6859, and AD. We 144 145 conducted a probit regression to examine the independent effect of rs6859, with the outcome adjusted for the 146 covariates based on an Akaike Information Criterion (AIC)-informed model (Cavanaugh and Neath, 2019). Alternatively, a linear regression was run similarly for estimating the pTau-181 relationship with SNP rs6859. 147 148 The covariates included were age, sex, years of education, marriage status (divorced and never married vs. married), smoking (yes/no), and alcohol use (yes/no). All possible combinations of covariates were run in the 149 150 model, and the model with the best AIC was selected. In the third step, the conditioned effects of rs6859 and 151 pTau-181 on the outcome variable were estimated in a probit regression model (Yin et al., 2016). Probit regression model is a non-linear model for estimating the probability of being assigned to either of the 152 153 categories of a dichotomous outcome. It is similar to the logistic model except for the relationship with the link 154 function, which is based on a cumulative Gaussian distribution (Oyekale, 2021). The main advantage of the probit model over the logistic model is that the former provides the probability of the event while treating the 155 covariate as a latent variable, while the odds ratio from the latter does not have the same interpretation (Yin et 156 al., 2016). The estimates from the probit regression model were presented as average marginal effects. Average 157 marginal estimates represent the average conditional probability associated with the variables represented on 158 159 the outcome scale (Williams, 2012). Lastly, the *mediate* function from the *mediation* package was used to 160 compute the mediation and proportion of mediated effects from the fitted models (Tingley et al., 2014).

#### 161

We estimated the parameters by keeping the GG genotype of SNP rs6859 as the reference genotype while 162 163 considering the GA/AA genotype (carriers of allele A) at greater risk for AD. These were coded as 0, 1, and 2, 164 and the mediation effects were computed on allele (A) counts as in an additive model. We also computed the 165 effects for AA genotype individuals while choosing the GG genotype as the reference category (GG vs. AA). The *mediation* package estimates an average effect for average causal mediation effects (ACME), average 166 167 direct effects (ADE), and an average for the proportion of the mediated effects by decomposing the precomputed SNP rs6859 and standardized pTau-181 effects on AD in the combined model estimation step. This 168 169 step was required to quantify how the association between rs6859 and AD is mediated by pTau-181. ACME 170 represents the indirect effect of the SNP rs6859 on AD routed through pTau. ADE is the effect of the SNP rs6859 on AD conditioned on the pTau-181. Similarly, the total effect is the sum of the direct and indirect 171 172 effects of rs6859 on AD. The proportion of the mediated effects is a complementary parameter to the ACME. 173 which simply quantifies the proportion of the mediated effect. A two-tailed p-value less than 0.05 was 174 considered significant for the regression models and mediation effects. The confidence intervals were estimated 175 with 5000 bootstrapped iterations with the boot option from the mediation package to obtain percentile 176 confidence intervals. We conducted a sensitivity analysis using the p values (correlation between the residuals derived from the rs6859-AD association and rs6859 plus pTau-181, including a model for AD) plotted against 177 178 ACME values with 5000 simulations using the *medsens* command from the same package to check the 179 robustness of the results to see if they follow the sequential ignorability assumption (Pearl 2014). 180

## 181 **3 Results**

182

#### 183 **3.1 Sample characteristics**

184 185 All participants with complete covariate information in the database were included in the analysis. The final 186 sample contained a total of 708 participants (Supplementary Figure S1). The pTau-181 level had a skewed 187 distribution with a median value of 34.20 pg/mL. There was a large variation in pTau-181 between individuals 188 (range: 6.9-213.0 pg/mL). The participant characteristics and demographic data are shown in Table 1. There 189 were 181 AD cases, accounting for 25.56% of the total sample. The frequencies for cognitively normal 190 individuals and individuals with cognitive deficiencies other than AD were 131 and 396, respectively. Participants were predominantly of the white race (94.06%) and males. Close to 95.90% of the participants had 191 192 a marriage history, and 32.76% reported having a history of smoking. The proportion of participants with 193 GA/AA genotypes of SNP rs6859 was 73.87%. For some participants, there were large pTau-181 variations as 194 measured by CV% statistics (Supplementary Figures S2-S3). For the sample pTau-181 (CV%), the median was 195 6.08 (95% CI: 4.81, 7.15). Regarding pTau-181 (daily CV%), the median value was 1.33 (95% CI: 0.56, 2.15). 196 When it comes to daily CV%, there was no notable difference for rs6859 polymorphisms. However, daily CV% 197 variations were larger for males, individuals of white race, married participants, and those with a history of smoking and alcohol use (Supplementary Figure S4). 198

The boxplot in Figure 1A illustrates the pTau-181 distribution for males and females. Females had relatively higher median pTau-181 levels compared to males (35.1 vs. 33.0). GA carriers constituted the highest number (357, or 50.42%) among the SNP rs6859 genotypes. The pTau-181 variation by age for carriers (GA/AA) and non-carriers (GG) of SNP rs6859 allele A are shown in Figure 1B. The Pearson correlation heatmap for all continuous variables is shown in Figure 2. There were no notable, strong correlations observed among the variables. SNP rs6859 was positively correlated with pTau-181, although this correlation was relatively modest. The SNP had a weak correlation with age (0.014) and education (-0.042), respectively.

206

#### 207 Table 1. Characteristics of participants in the study sample (n=708)

Parameter	Mean (Frequency)	SD	Range
Age (Years) <sup>#</sup>	74.19	7.19	55.33-90.79
Male (%)	399 (56.36%)		
Female (%)	309 (43.64%)		

Education (Years)	15.94	2.87	4-20
Marriage Status			
Ever	679 (95.90%)		
Never	28 (3.95%)		
Unknown	1 (0.14%)		
Race			
White	666 (94.06%)		
Other	42 (5.93%)		
Smoking (Ever)	232 (32.76%)		
Smoking (Never)	476 (67.24%)		
Alcohol (Ever)	29 (4.10%)		
Alcohol (Never)	679 (95.90%)		
pTau-181 (pg/mL) <sup>#</sup>	34.20 (95% CI: 32.0, 35.1)	26.17	6.9 - 213.0
pTau-181 (CV%) <sup>#</sup>	6.08 (95% CI: 4.81, 7.15)	17.15	0.0 - 77.6
pTau-181 (daily CV%) <sup>#</sup>	1.33 (95%: 0.56, 2.15)	8.37	0.00 - 82.68
SNP rs6859 (Genotype Frequencies)			
GG	185 (26.12%)		
GA	357 (50.42%)		
AA	166 (23.44%)		
SNP rs6859 (Allele Frequencies) <sup>\$</sup>			
G	51.34%		
А	48.66%		

Note. Data are presented as mean  $\pm$  standard deviation (SD) or percentage (%) for continuous and categorical variables, respectively; <sup>#</sup> Age and pTau-181 are presented as median and IQR due to skewness of distributions.

95% CI for median was calculated using the bootstrap method. <sup>\$</sup>Allele frequencies show the frequencies of SNP
 rs6859 alleles in the analysed sample.



213

Figure 1. (A) Distribution of pTau-181 by gender in the ADNI cohort (B) Variation of pTau-181 distribution by age and rs6859 genotype in the study sample



216

217

Figure 2. Correlation plot showing the relation for rs6859 with pTau-181 and other covariates in the ADNI dataset. Note. The size and colour of the circle indicate the strength and direction of the correlation between variables. The large dark blue dots show maximum correlation, i.e., correlation between the same variables in this case.

222

# 223 3.2 The association of the SNP rs6859 with AD

We found a statistically significant association between the SNP rs6859 and AD in the adjusted probit model. 224 225 We compared the model with a complete set of covariates to the best model, which is the model with the 226 minimal set of variables that best fits the data. The AIC - based model selection process is shown in Figure 3, 227 which illustrates the best model selection using the Akaike weights interpreted as the conditional probabilities 228 pertaining to the different combinations of the covariates (Wagenmakers and Farrell 2004). Of these, the best 229 model identified contained rs6859 and education (Supplementary Table S1). The AIC difference between the 230 models was close to 10 (Supplementary Table S2). The predicted z-score from the probit regression was 0.25 231 (95% CI: 0.11, 0.39, p<0.001), which conveyed a higher probability of being classified as AD for the SNP 232 rs6859 additive model (A risk allele). Thus, the first requirement of the rs6859, which is that the former should 233 be significantly associated with both AD and pTau-181, is satisfied. The converted probit coefficients of 234 average marginal effects for the full model are presented in Supplementary Figure S5. The average marginal 235 effect estimates the percentage probability from the probit coefficients while keeping the effects from other 236 variables constant. As per the average marginal effects from the best model, there was a 7.9% higher percentage 237 probability of 0.079 (95% CI: 0.035,0.124, p<0.001) for AD associated with the genotype change from GG to 238 AA in the SNP rs6859. The only other important variable in this model was increasing years of education. 239 which showed a 1.3 decreased percentage probability of being classified as AD, -0.013 (95% CI: -0.024, -0.002, 240 p<0.05).

241

#### 242 3.3 The association of SNP rs6859 with pTau-181

243 For evaluating the model associations for SNP rs6859 with pTau-181, we ran linear regression models. The 244 model selection using Akaike weights is illustrated in Figure 4. SNP rs6859, age, race, and sex were selected as 245 the most significant predictors of pTau-181 in the best subset model. The AIC difference between the models 246 favored the model with a reduced set of covariates. The AIC for the different models is given in Supplementary 247 Table S3. In the age and sex-adjusted model, an increase in the dose of the A allele of the SNP rs6859 was 248 associated with an increase in the pTau-181 level. Respective coefficients and confidence limits for both models 249 are presented in Figure 5. Our analysis of the association between rs6859 and standardized pTau-181 levels was 250 statistically significant in the multivariate model and, therefore, independent of other risk factors, such as age 251 and smoking. The genotype change (GG to AA) of the rs6859 resulted in about a 0.144 increase per SD of 252 pTau-181 (95% CI: 0.041, 0.248, p<0.01). Female participants were more likely to accumulate pTau-181 than 253 males. pTau-181 accumulation was comparatively higher in white individuals (0.277, 95% CI: -0.031, 0.586, 254 p=0.078). However, the coefficient was not statistically significant. Surprisingly, a year of the increase in age 255 was associated with a reduction in pTau-181 (-0.011, 95% CI: -0.021, -0.001; p<0.05). Therefore, we ran a 256 linear mixed model with a larger sample size (records = 2189, n=1249) to confirm the association 257 (Supplementary Figure S6). Age, gender, education, and race were adjusted in the analysis. This dataset did not 258 include rs6859 information. Here, an increase in age predicted a 0.008 increase in pTau-181 (95% CI: 0.001, 259 0.015, p<0.05). Our findings show that the diminished association for pTau-181 with age likely occurred as a 260 result of the smaller sample size arising from linking covariate information.



262

Figure 3. Model selection table depicting the AIC based variable selection process for the SNP rs6859 with AD. Note. The plot shows the model selection process in the automated model, ranked using AIC. Several models were run for different combinations of covariates (right-hand x-axis shown in each row), and a best subset model was selected. The models with a higher cumulative model weight indicate the best models. The best models are ranked in ascending order on the right-hand side of the plot. The row colours represent coefficient values, following a schema akin to a correlation heatmap, where blue signifies negative values and red denotes positive values. The model 37 carries the maximum weight of 0.075. The white row represents blank cells.

270



Figure 4. Model selection table depicting the AIC-based variable selection process for the rs6859 association with standardized pTau-181 (n=708). The plot shows the model selection process in the automated model, ranked using AIC. Several models were run for different combinations of covariates (right-hand x-axis shown in each row) and the best subset model was selected. The models with the higher cumulative model weights indicate the best model. The best models are ranked in ascending order on the right-hand side of the plot. Colors depict coefficient values, following a schema akin to a correlation heatmap, where blue signifies negative

- values and red denotes positive values. Grey color is used to represent categorical variables. The model 114
- 279 carries a maximum weight of 0.066. The white row represents blank cells.
- 280

281



282



#### 284 3.4 Associations between the outcome, treatment variable, and dependent variable

285 For this analysis, we included the SNP rs6859 with standardized pTau-181 as covariates to generate estimates to be used later in the causal mediation analysis. The predicted z-score from the probit model was significant 286 287 for both the rs6859 and mediator variables. The allele changes from G to A for the SNP rs6859 remained similar to the previously computed estimate for AD (0.229, 95% CI: 0.081, 0.378, p<0.01). For each standard 288 289 deviation change in pTau-181, there was a higher z-score, implying a higher probability of being classified as AD (0.328, 95% CI: 0.225, 0.434, p<0.001). Associated probabilities for SNP rs6859 and pTau-181 were 290 291 6.84% (95% CI: 2.49, 11.18, p<0.01) and 9.79% (95% CI: 6.88%, 12.70%, p<0.001), respectively. The predicted effects from this model were visualized in the accompanying plot (Figure 6), showing an increase in 292 293 predicted risk associated with the unit change in rs6859 and pTau-181. As the model estimates were significant 294 for both rs6859 and pTau-181, the relationship is suggestive of a partial mediating effect as opposed to a full 295 mediating effect.

296



298

Figure 6. Conditioned effect plot illustrating the association of AD with rs6859 and pTau-181. Note. The plot was generated from a probit model with SNP rs6859 and pTau-181 as covariates. In Figure A, the dark blue line and surrounding light blue colour show the relationship and associated 95% confidence intervals for the genotype change and AD, respectively. In Figure B, the dark blue line shows the relationship and associated 95% confidence intervals between pTau-181 and AD. The black colour lines in the x-axis for Figure A and Figure B correspond to observed values. The y-axis shows the estimates from the probit regression. A higher positive coefficient implies a higher AD probability.

306

# 307 3.5 Findings from the causal mediation analysis308

309 The estimands from the CMA are reported in Table 2. The variation in the SNP rs6859 predates the pTau-181 and AD. Therefore, SNP rs6859 variations could be considered a natural randomization and therefore do not 310 311 have any direct influence on either the pTau-181 or AD. The estimates, as previously described, were generated 312 from simulations, and the results indicate that the ACME, ADE, and total effect were significantly different 313 from zero. Furthermore, the estimates could be interpreted as population averages for the specific genotypes 314 (GG vs. AA) under a counterfactual scenario, i.e., the difference in average effects by holding the genotype 315 effects for the AD, but switching between the values of pTau-181 observed with either of the genotypes 316 (Tingley et al., 2014; Zhang et al., 2016). As hypothesized, both the ACME and ADE were higher for the AA 317 compared to the GG genotype and were statistically significant. The ACME for both allele variations was 0.025 and 0.033 (p<0.01), respectively. Here, ACME represents the linear chain of effects of the specific genotype on 318 319 AD probability, which is indirectly affected by pTau-181. It is to be noted that pTau-181 in turn is associated 320 with the genotype in question. The ACME estimate informs us that there is statistically significant evidence for 321 pTau-181 mediating the observed association of SNP rs6859 with AD. On top of that, the ADE was also significant and slightly higher for the AA genotype. Therefore, this suggests that the risk predicted for allele 322 323 change in SNP rs6859 was partly mediated through pTau-181. The proportion of average-mediated effect was 17.0% and was higher for the AA genotype (19.4%; 95% CI: 6.2%, 43.0%, p<0.01). For the analysis between 324 325 carriers and non-carriers shown in Supplementary Figure S7, the ACME was again statistically significant and 326 high for the carrier group (0.024 vs. 0.018, p<0.01). The corresponding proportions of the mediated effects were 327 18.98% and 14.56%, respectively.

328

Table 2. Causal mediation analysis showing the estimate of the effect on the association between rs6859 and
 Alzheimer's Disease mediated through pTau-181 (n=708)

Effect	Estimate	95% Lower CI	95% Upper CI	р
ACME (GG)	0.025	0.007	0.050	0.003**

ACME (AA)	0.033	0.009	0.060	0.003**
ADE (GG)	0.137	0.052	0.220	0.002**
ADE (AA)	0.145	0.055	0.230	0.00**
Total Effect	0.170	0.082	0.260	0.000***
Prop. Mediated (GG)	0.147	0.042	0.380	0.003**
Prop. Mediated (AA)	0.194	0.062	0.430	0.003**
ACME (average)	0.029	0.009	0.050	0.003**
ADE (average)	0.141	0.054	0.230	0.002**
Prop. Mediated (average)	0.170	0.052	0.410	0.003**

332

333 Note. The mediation estimates were jointly computed from separate regression model fits for AD and pTau as 334 outcomes. For the AD outcome, an independent effect of rs6958 conditioned for pTau was estimated with the 335 probit model. The independent effect of rs6958 on standardised pTau was calculated from a multivariate linear regression model. \*\*p<0.01; \*\*\*p<0.001. ACME (Average Causal Mediation Effect) indicates the part of the 336 337 rs6859 effect that is mediated by pTau-181. ADE (Average Direct Effect) refers to the part of the effect that is 338 independent of the pTau-181. Total Effect includes both the direct and indirect effects of rs6859. Proportion 339 Mediated is calculated as the ratio of the ACME to the total effect, representing the proportion of the effect that 340 passes through pTau-181 due to rs6859.

341

#### 342 **3.6** Sensitivity analysis for violation of the sequential ignorability assumption

343 A sensitivity analysis was carried out to check for the presence of unobserved confounders in the single 344 mediator model (as per Cox et al. 2013). The results are presented in Supplementary Figure S8. For this 345 purpose, a model correlation parameter  $\rho$  was calculated from the residuals of the models used to compute the 346 combined model. The values of the model parameter  $\rho$  were plotted on the x-axis against ACME on the y-axis. The interpretation is based on the specific p values at which the ACME becomes zero or changes sign (positive 347 348 to negative). The corresponding  $\rho$  values were 0.2 and 0.3 for the former and latter, respectively. According to 349 the previous literature, the  $\rho$  values indicate that the estimands are relatively robust to the sequential ignorability 350 assumption, and there is evidence of a positive mediation effect (Imai and Yamamoto, 2013; Zhang et al., 351 2016).

352

#### 353 4. Discussion

354

355 Herein, we investigated a possible mechanistic link between the previously observed association between the 356 SNP rs6859 in the NECTIN2 gene and AD, using pTau as a mediator of the rs6859 effect on AD. Tauopathies 357 are recognised players in neurologic disorders (Hernández and Avila, 2007). There is substantial evidence of 358 associations between pTau-181 state changes and AD-relevant markers, often decades before the development 359 of aggregated tau pathology in the brain (Barthélemy et al., 2020). Despite this, it is still not clear if pTau 360 build-up directly causes AD or if it is driven by alternative biological mechanisms (Jack et al., 2018). To our 361 knowledge, this is the first study to uncover a causal role for pTau-181 in AD from the association between variation in the NECTIN2 gene and AD using the CMA approach. This CMA revealed that 17.05% of the 362 363 rs6859 effect on AD is mediated through the pTau. Our results thus suggest that the accumulation of pTau is a partial cause of AD, and other, including unknown, pathways likely contribute to AD too. The latter is rather 364 expected since AD is a heterogeneous complex health disorder and may include cases of different etiology. 365

366 Several ptau isoforms exist that could be utilized to study Alzheimer's disease (AD) pathology (Suárez Calvet et al., 2020; Hirota et al., 2022b; Salvadó et al., 2024). Numerous studies have explored the utility of these 367 368 markers over the years, often yielding conflicting results (Hampel et al., 2004; Vacchiano et al., 2023; 369 **Ingannato** et al., 2024; Salvadó et al., 2024). Consequently, there is still debate regarding the best marker for 370 AD, and new candidates are continually being proposed (Suárez Calvet et al., 2020; Karikari et al., 2021; Salvadó et al., 2024). Assessing the diversity of ptau isoforms in relation to AD pathology is challenging, as 371 372 these isoforms appear at different stages of AD and exhibit heterogeneous relationships with amyloid plaques 373 and neurofibrillary tangles (Wennström et al., 2024). For instance, an earlier study comparing phosphorylation 374 at threonine 231 (p-tau231), threonine 181 (p-tau181), and serine 199 (p-tau199) in cerebrospinal fluid (CSF) 375 showed that ptau181 could classify AD with Lewy body dementia better than p-tau231, which differentiated 376 AD from frontotemporal dementia. However, from a clinical prediction viewpoint, these markers were only 377 useful as standalone markers (Hampel et al., 2004).

378 In mouse models, these markers were shown to be associated with synaptic dysfunction mediated by amyloid- $\beta$ , with ptau181 specifically indicating axonal dysfunction (Hirota et al., 2022). Another study among Swedes 379 380 demonstrated that ptau217 better reflected amyloid pathology and neurodegeneration than ptau181 and could 381 more effectively classify AD from other neurodegenerative conditions (Janelidze et al., 2020). Later, this 382 finding was validated using plasma samples. (Thijssen et al., 2021). However, both ptau181 and ptau217 share 383 similar pathology and increase before tau accumulation in AD (Janelidze et al., 2020; Horie et al., 2021). A 384 Canadian study detected CSF-based ptau231 changes before other biomarkers in AD as a response to amyloid-385  $\beta$ -initiated pathology (Ashton *et al.*, 2022). Despite their classification ability, these markers do not directly 386 translate to sensing disease severity. For example, postmortem examinations of AD brains showed that ptau231 387 did not robustly indicate AD severity (Buerger et al., 2002).

388 Thus, selecting the ideal ptau isoform is critical for addressing the temporality question and capturing early onset and progression in AD. We chose ptau181 as a biomarker because it is considered a "classical AD 389 marker" and is the only ptau isoform currently measured among ADNI CSF biomarkers (Zetterberg and 390 391 **Blennow**, 2021). Plasma ptau181 levels have been demonstrated to outperform the A642/A640 ratio, another 392 important AD biomarker.(Thijssen et al., 2020). Importantly, plasma ptau181 levels can capture early dementia 393 and are elevated in APOE4 carriers, showing its pathological involvement in AD (Ingannato et al., 2024). 394 Ptau181 correlates with neurodegeneration and cognitive decline in AD.(Moscoso et al., 2021). Ptau181 assays 395 have demonstrated reliable prediction of AD progression. (Janelidze et al., 2023). Furthermore, CSF-based ptau181 is not influenced by other neurological conditions, unlike its plasma counterpart (Vacchiano et al., 396 397 2023), and captures clear AD signatures compared to other dementias. (Zetterberg, 2017). All this evidence 398 shows that ptau181 is indeed a robust and tested marker of AD pathology (Thijssen et al., 2021; Yu et al., 399 2023).

400 Salvadó et al. utilized a machine learning algorithm to create a biological staging model for AD using 401 information from several biomarkers to predict AD progression. Their final set of biomarkers, however, did not 402 include ptau181 and p-tau231, as their contribution to the model was marginal. Interestingly, the  $A\beta 42/40$  ratio 403 and p-tau217 remained part of their list (**Salvadó** *et al.*, **2024**). Therefore, more studies are required to validate 404 and mechanistically understand how these isoforms relate to AD. Future research could use some of the 405 markers from Salvadó et al.'s study as mediators to replicate our work. However, it is difficult to say at this 406 stage whether these associations would yield a stronger causal relationship.

407 Another important gap is the lack of information regarding the tau form that can be labelled as representing 408 potential "post-infectious dementia". We are unaware of any specific study conducted on this topic to date. 409 Based on current evidence, we believe that the effect of infections on AD is primarily through inflammation, 410 which promotes AD pathological features like A $\beta$  and ptau production (**Cairns, Itzhaki and Kaplan, 2022b**; 411 **Ganz, Fainstein and Ben-Hur, 2022**). Therefore, we hypothesize that a ptau isoform that best correlates with 412 inflammation could be a suitable predictor.

413 It is important to emphasize that we selected pTau-181 as a candidate mediator of the effect of rs6859 in the 414 *NECTIN2* gene on AD because both pTau and the *NECTIN2* gene have been linked to AD, as well as to 415 infections, in the literature (**Yashin et al., 2018; Sathler et al., 2022; Tang et al., 2022)**. From our previous

416 works, we also showed that upon vaccination for pneumonia and flu, rs6859 A allele carriers experienced a

417 reduced risk for AD (Ukraintseva et al., 2023). Additionally, carriers of the A allele were likely to experience cognitive decline, albeit at different rates (Rajendrakumar et al., 2024). In our study, the presence of the AA 418 419 genotype of the SNP rs6859 was associated with an increased percentage probability for AD (by 7.9%) 420 compared to the GG genotype, which is in line with previous findings from other cohorts (Yashin et al., 2018; 421 Logue et al., 2011). The increased pTau-181 levels in carriers of the rs6859 A allele are, however, not yet well 422 understood. Our results do not exclude the possibility that this increase in pTau may reflect a higher 423 vulnerability to infections as another underlying cause of AD. One hypothetical explanation could be that the 424 variation in the NECTIN2 gene might increase the host vulnerability to infections, e.g., herpesviruses, which in

- 425 turn may promote neural damage and pTau accumulation in the brain, contributing to neurodegeneration
  426 (Cairns, Itzhaki, and Kaplan, 2022; Powell-Doherty et al., 2020; Ogawa et al., 2022; Liu et al., 2018;
- 427 Readhead et al., 2018; Goldhardt et al., 2023). This potential mechanism deserves further investigation.

428

429 One should note that the CMA is not the only way to uncover causal relationships from the observed associations. Mendelian randomization (MR) is another common approach. We, however, preferred the CMA 430 for this study because it provided a more attractive option to test the putative causal pathways, given the 431 432 possible role of confounding associations with the observed findings for SNP rs6859 with pTau-181 and AD 433 (Sait et al., 2021). The CMA, at least in theory, is less stringent than the assumptions associated with MR 434 studies, which assume a much stricter instrument variable and an intermediate outcome pathway (Rijnhart et 435 al., 2021). The CMA with an ideal "treatment" should produce estimates similar to those in the MR (Carter et 436 al., 2021). Additional strengths of this study include the availability of longitudinal biomarker measurements in 437 the ADNI and the use of sensitivity analysis. An important limitation of this study is the incomplete data on 438 covariates for some ADNI participants, which led to a smaller sample size than initially expected. Other 439 limitations include the lack of supporting evidence for our findings, particularly regarding how the NECTIN2 440 SNP rs6859 affects the production, processing, and deposition of beta-amyloids, and its modulation of  $\beta$ -441 secretase (BACE1) activity. Furthermore, the Nectin2 protein, the end product of this gene, is not measured in 442 ADNI. Measuring Nectin2 protein levels could provide additional downstream insights. To address these gaps, 443 we plan to conduct future studies examining the relationship between SNP rs6859, beta-amyloids, and 444 hippocampal volume to better understand NECTIN2's impact on AD phenotypes.

445

446 In conclusion, this study revealed a new causal relationship between pTau-181 and AD that partly explains the 447 association of the rs6859 polymorphism in the NECTIN2 gene with Alzheimer's disease. Our findings in ADNI 448 data further strengthen the evidence of the association between rs6859 and AD, previously reported in GWAS 449 of other human cohorts (Yashin et al., 2018; Logue et al., 2011; Xiao et al., 2022), and provide a plausible 450 pathway linking the *Nectin2* polymorphism with AD. Predictably, the association between rs6859 and AD was only partly mediated by pTau. The rest of the effect may be mediated through other, yet unknown, factors. 451 452 Further research is needed to uncover the remaining mechanisms connecting the variation in the NECTIN2 gene 453 with AD. 454

#### 455 Data availability statement

- 456
- 457 The data used in this article is publicly accessible through the ADNI website (<u>http://adni.loni.usc.edu</u>).
- 458

#### 459 Ethics statement

460 The samples were collected with the written informed consent of all participants. Informed consent was 461 obtained from all subjects and/or their legal guardian(s). ADNI studies follow Good Clinical Practices 462 guidelines, the declaration of Helsinki and United States regulations (U.S. 21 CFR Part 50 and part 56). ADNI 463 studies were approved by all the respective Institutional Review Boards of academic institutions involved in the 464 consortium. For our specific study, we received approval from the Duke University Health System Institutional 465 Review Board under the Protocol IDs Pro00109279 and Pro00105389.

466

#### 467 Author Contributions

#### 468

469 S.U. and A.L.R. conceived the study. K.A., O.A.B., and A.L.R. were involved in data curation, analysis, and 470 data interpretation. S.U., K.A., and A.I.Y. provided guidance on data analysis and critically revised the 471 manuscript. All authors read and approved the final version of the manuscript.

472

## 473

#### 474 Funding

475

Research reported in this publication was supported by the National Institute on Aging of the National Institutes
of Health under Award Numbers R01AG076019, R01AG070487. The content is solely the responsibility of the

- 478 authors and does not necessarily represent the official views of the National Institutes of Health.
- 479

#### 480 Abbreviations

ACME	Average Causal Mediation Effects
AD	Alzheimer's Disease
ADE	Average Direct Effects
AIC	Akaike Information Criterion
Αβ	Amyloid βeta
BACE1	β-secretase
CV%	Coefficient of Variation Percentage
GWAS	Genome-wide association studies
HSV	Herpes Simplex Virus
IQR	Interquartile Range
рТаи	Phosphorylated Tau
SD	Standard Deviation
SNP	Single Nucleotide Polymorphism
NECTIN2	Nectin Cell Adhesion Molecule 2 (gene)

481 482

#### 483 Acknowledgements

484

485 The authors would like to thank the ADNI team. Data collection and sharing for this project was funded by the 486 Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National 487 488 Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; 489 490 Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai 491 Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its 492 affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy 493 Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; 494 Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda 495 496 Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is 497 providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the 498 Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern 499 California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic 500 Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. 501

#### 503 Conflict of interest

504

502

505 The authors declare that they have no competing interests. 506

#### 507 **Supplementary material**

509 Supplementary Figure S1. Study flow diagram showing the final sample selection in the ADNI cohort. 510 **Supplementary Figure S2.** Histogram showing daily Measurement variation for pTau-181 Indicated by CV%. 511 **Supplementary Figure S3.** Histogram Showing the overall sample variation for pTau-181 indicated by CV%. 512 **Supplementary Figure S4.** Boxplots showing daily CV% variation of pTau-181 for categorical variables. 513 **Supplementary Figure S5.** Average marginal estimates derived from the full variable probit regression model 514 for the prediction of AD. Supplementary Figure S6. Association of pTau-181 and age estimated from the 515 linear mixed models with sex, race, education, and smoking history as covariates assuming varying subject-516 specific intercepts. Supplementary Figure S7. Contrasts in estimates of causal mediation analysis for SNP 517 rs6859 between carriers of GA/AA genotype and GG genotype with AD mediated through Ptau-181. 518 **Supplementary Figure S8.** Sensitivity analysis plot illustrating the model parameter  $\rho$  for checking the 519 sequential ignorability assumption. Supplementary Table S1. Estimates from the probit regression model for 520 SNP rs6859 association with AD from the selected AIC model. Supplementary Table S2. AIC for all the 521 different models explored for determining associations with the AD and SNP rs6859 using the probit model. 522 Supplementary Table S3. AIC for all the different models explored for determining associations with the 523 standardized Tau and SNP rs6859 using the linear regression model.

524

#### 525 References

- 526
- Ashton, N.J. *et al.* (2022) 'Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in
  Alzheimer's disease', *eBioMedicine*, 76, 103836. doi: 10.1016/j.ebiom.2022.103836
- 529 Barthélemy, N.R. *et al.* (2020) A soluble phosphorylated tau signature links tau, amyloid and the evolution of 530 stages of dominantly inherited Alzheimer's disease, *Nat.Med*, 26, 398–407. doi.org/10.1038/s41591-020-0781-z
- Bartoń, K. (2013) *MuMIn: Multi-model inference, R package version 1.10.0.* https://cran.r project.org/web/packages/MuMIn/index.html [Accessed April 4, 2023]
- Buerger, K. *et al.* (2002) 'Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau
  protein phosphorylated at threonine 231', *Arch Neurol*, 59(8), 1267–1272. doi: 10.1001/archneur.59.8.1267
- Cairns, D.M., Itzhaki, R.F. and Kaplan, D.L. (2022) 'Potential Involvement of Varicella Zoster Virus in
  Alzheimer's Disease via Reactivation of Quiescent Herpes Simplex Virus Type 1', *J Alzheimer's Dis*, 88(3),
  1189–1200. doi.org/10.3233/jad-220287
- Carter, A.R. *et al.* (2021) Mendelian randomisation for mediation analysis: current methods and challenges for
   implementation, *Eur J Epidemiol*, 36, 465–478. doi.org/10.1007/S10654-021-00757-1
- Cavanaugh, J.E. and Neath, A.A. (2019) The Akaike information criterion: Background, derivation, properties,
  application, interpretation, and refinements, *WIREs Comput Stat*, 11: e1460. doi.org/10.1002/wics.1460
- Chang, C.C. *et al.* (2015) Second-generation PLINK: Rising to the challenge of larger and richer datasets, *GigaScience*, 4(1), s13742–015–0047–8. doi.org/10.1186/s13742-015-0047-8
- Cox, M.F. *et al.* (2022) Friend or Foe? Defining the Role of Glutamate in Aging and Alzheimer's Disease, *Front Aging*, 3(929474). doi.org/10.3389/fragi.2022.929474
- Cox, M.G. *et al.* (2013) Sensitivity Plots for Confounder Bias in the Single Mediator Model, *Eval Rev*, 37(5),
  405-431. doi.org/10.1177/0193841x14524576
- Drummond, E. *et al.* (2020) Phosphorylated tau interactome in the human Alzheimer's disease brain, *Brain*,
  143(9), 2803–2817. doi.org/10.1093/brain/awaa223
- Ganz, T., Fainstein, N. and Ben-Hur, T. (2022) 'When the infectious environment meets the AD brain', *Mol Neurodegeneration*, 17(1),53. doi: 10.1186/s13024-022-00559-3
- 552 Goldhardt, O. et al. (2023) Herpes simplex virus alters Alzheimer's disease biomarkers A hypothesis paper,
- 553 Alzheimer's Dement, 19(5), 2117–2134. doi.org/10.1002/alz.12834

- Grothe, M.J. *et al.* (2021) Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer
  Disease Neuropathology at Autopsy, *Neurology*, 97(12), e1229–e1242.
  doi.org/10.1212/wnl.00000000012513
- Hampel, H. *et al.* (2004) 'Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof
  Alzheimer Disease: A Comparative Cerebrospinal Fluid Study', *Arch Gen Psychiatry*, 61(1), 95–102. doi:
  10.1001/archpsyc.61.1.95
- Hernández, F. and Avila, J. (2007) Tauopathies, *Cell Mol Life Sci*, 64, 2219–2233. doi.org/10.1007/s00018007-7220-x
- Hirota, Y. *et al.* (2022) Distinct brain pathologies associated with Alzheimer's disease biomarker-related
   phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-β amyloidosis, *Brain commun*, 4(6): fcac286. doi.org/10.1093/braincomms/fcac286
- Horie, K. *et al.* (2021) 'CSF tau microtubule binding region identifies tau tangle and clinical stages of
  Alzheimer's disease', *Brain*, 144(2), 515-527. doi: 10.1093/brain/awaa373
- Imai, K. and Yamamoto, T. (2013) Identification and Sensitivity Analysis for Multiple Causal Mechanisms:
   Revisiting Evidence from Framing Experiments, *Political Analysis*, 21, 141–171. doi.org/10.1093/pan/mps040
- Ingannato, A. *et al.* (2024) 'Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia', *Front Endocrinol (Lausanne)*, 15(1375302).
- Jack, C.R. *et al.* (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease,
   *Alzheimers Dement*, 14(4), 535–562. doi.org/10.1016/j.jalz.2018.02.018
- Janelidze, S. *et al.* (2020) 'Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease', *Nat Commun*, 11(1) 1683. 10.1038/s41467-020-15436-0
- Janelidze, S. *et al.* (2023) 'Head-to-head comparison of 10 plasma phospho-tau assays in prodromal
  Alzheimer's disease', *Brain*, 146(4), 1592–1601. doi: 10.1093/brain/awac333
- Karikari, T.K. *et al.* (2021) 'Head-to-head comparison of clinical performance of CSF phospho-tau T181 and
  T217 biomarkers for Alzheimer's disease diagnosis', *Alzheimers Dement*, 17(5), 755–767. doi:
  10.1002/alz.12236
- Lee, S.E. *et al.* (2022) Zika virus infection accelerates Alzheimer's disease phenotypes in brain organoids, *Cell Death Discov*, 8, 153. doi.org/10.1038/s41420-022-00958-x
- Liu, C. *et al.* (2018) Genome-Wide Association and Mechanistic Studies Indicate That Immune Response
  Contributes to Alzheimer's Disease Development, *Front Genet*, 9(410). doi.org/10.3389/fgene.2018.00410
- Logue, M.W. *et al.* (2011) A Comprehensive Genetic Association Study of Alzheimer Disease in African
   Americans, *Arch Neurol*, 68(12), 1569-1579. doi.org/10.1001/archneurol.2011.646
- Mancuso, R. *et al.* (2022) Editorial: Infection, inflammation, and neurodegeneration: A critical path to
  Alzheimer's disease, Volume II, *Front Aging Neurosci*, 14:1044047. doi.org/10.3389/fnagi.2022.1044047
- 588 Mizutani, K. *et al.* (2022) Nectin-2 in general and in the brain, *Mol Cell Biochem*, 477(1), 167–180.
   589 doi.org/10.1007/s11010-021-04241-y
- Moore, K.B.E., Hung, T.J. and Fortin, J.S. (2023) Hyperphosphorylated tau (p-tau) and drug discovery in the
  context of Alzheimer's disease and related tauopathies, *Drug Discov Today*, 28(3):103487.
  doi.org/10.1016/j.drudis.2023.103487
- 593 Moscoso, A. et al. (2021) 'Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament
- Light Chain With Neurodegeneration in Alzheimer Disease', JAMA Neurol, 78(4), 396–406. doi:
   10.1001/jamaneurol.2020.4986

- 596 Nguyen, T.Q., Schmid, I. and Stuart, E.A. (2020) Clarifying causal mediation analysis for the applied
- 597 researcher: Defining effects based on what we want to learn HHS Public Access, Psychol Methods, 16,
- 598 10.1037/met0000299. doi.org/10.1037/met0000299
- Nuovo, G.J. *et al.* (2022) The amplification of CNS damage in Alzheimer's disease due to SARS-CoV2
   infection, *Ann Diagn Pathol*, 61:152057. doi.org/10.1016/j.anndiagpath.2022.152057
- Ogawa, H. *et al.* (2022) Nectin-2 Acts as a Viral Entry Mediated Molecule That Binds to Human Herpesvirus
  6B Glycoprotein B, *Viruses*, 14(1):160. doi.org/10.3390/v14010160
- Oyekale, A.S. (2021) Willingness to Take Covid-19 Vaccines in Ethiopia: An Instrumental Variable Probit
   Approach, *Int J Environ Res Public Health*, 18(17):8892. doi.org/10.3390/ijerph18178892
- Pearl, J. (2014) Interpretation and Identification of Causal Mediation, *Psychological Methods*, 19(4), 459–481.
  doi.org/10.1037/a0036434
- Piekut, T. et al. (2022) Infectious agents and Alzheimer's disease, J Integr Neurosci., 21(2):
  73.doi.org/10.31083/j.jin2102073
- Popov, V.A. *et al.* (2024) Prior infections are associated with smaller hippocampal volume in older women,
   *Front Dement*, 3(2024). doi.org/10.3389/frdem.2024.1297193
- 611 Powell-Doherty, R.D. *et al.* (2020) Amyloid-β and p-Tau Anti-Threat Response to Herpes Simplex Virus 1
  612 Infection in Primary Adult Murine Hippocampal Neurons, J Virol, 94(9), e01874-19.
  613 doi.org/10.1128/jvi.01874-19
- Purcell, S. and Chang, C. (2023). *PLINK 1.9.* https://www.cog-genomics.org/plink/1.9/ [Accessed April 4, 2023].
- 616 Rajendrakumar, A. L., Arbeev, K. G., Bagley, O., Yashin, A. I., Ukraintseva, S., (2024). The SNP rs6859 in
- NECTIN2 gene is associated with underlying heterogeneous trajectories of cognitive changes in older adults.
   *BMC Neurol*, 24(1), 78. doi: 10.1186/s12883-024-03577-4
- Ramos Bernardes da Silva Filho, S. *et al.* (2017) Neuro-degeneration profile of Alzheimer's patients: A brain
  morphometry study, *NeuroImage Clin*, 15, 15–24. doi.org/10.1016/j.nicl.2017.04.001
- R Core Team (2021) *R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.* Available at: https://www.R-project.org/ (Accessed: 15 May 2023).
- Readhead, B. *et al.* (2018) Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of
  Molecular, Genetic, and Clinical Networks by Human Herpesvirus, *Neuron*, 99(1), 64-82.
  doi.org/10.1016/j.neuron.2018.05.023
- Rijnhart, J.J.M. *et al.* (2021) Mediation analysis methods used in observational research: a scoping review and
  recommendations', *BMC Med Res Methodol*, 21(226). doi.org/10.1186/S12874-021-01426-3
- Sait, A. *et al.* (2021) Viral Involvement in Alzheimer's Disease, ACS Chem Neurosci, 12(7), 1049–1060.
  doi.org/10.1021/acschemneuro.0c00719
- Salvadó, G. *et al.* (2024) 'Disease staging of Alzheimer's disease using a CSF-based biomarker model', *Nat Aging*, 4(5), 694–708. doi.org/10.1038/s43587-024-00599-y
- Sathler, M.F. *et al.* (2022) HIV and FIV glycoproteins increase cellular tau pathology via cGMP-dependent
   kinase II activation, *J Cell Sci*, 135(12): jcs259764. doi.org/10.1242/jcs.259764
- Shaw, L.M. *et al.* (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging
  initiative subjects, *Annals of Neurology*, 65(4), 403–413. doi.org/10.1002/ana.21610
- 636 Shen, W.-B. et al. (2022) SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer's-like
- 637 neuropathology, *bioRxiv: [Preprint]*, (2022.01.31.478476). doi.org/10.1101/2022.01.31.478476

- 538 Suárez Calvet, M. et al. (2020) 'Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial
- 639 stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected',
- 640 EMBO Mol Med, 12(12), e12921. doi: 10.15252/emmm.202012921
- Tang, Z. *et al.* (2022) Treponema denticola Induces Alzheimer-Like Tau Hyperphosphorylation by Activating
  Hippocampal Neuroinflammation in Mice, J Dent Res, 101(8), 992–1001.
  doi.org/10.1177/00220345221076772
- Thijssen, E.H. *et al.* (2020) 'Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and
  frontotemporal lobar degeneration', *Nat Med*, 26(3), 387-397. doi: 10.1038/s41591-020-0762-2
- Thijssen, E.H. *et al.* (2021) 'Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in
  Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study',
- 648 *Lancet Neurol*, 20(9), 739–752.
- Tingley, D. *et al.* (2014) mediation: R package for causal mediation analysis, *Journal of Statistical Software*, 59
  (5), 1–38. doi.org/10.18637/jss.v059.i05
- Ukraintseva, S. *et al.* (2023) Vaccination Against Pneumonia May Provide Genotype-Specific Protection
   Against Alzheimer's Disease, *J Alzheimers Dis.*, 96(2), 499–505. doi.org/10.3233/jad-230088
- Vacchiano, V. *et al.* (2023) 'Elevated plasma p-tau181 levels unrelated to Alzheimer's disease pathology in amyotrophic lateral sclerosis', *J* Neurosurg *Psychiatry*, 94(6), pp. 428–435. doi: 10.1136/jnnp-2022-330709
- Wagenmakers, E.-J. and Farrell, S. (2004) AIC model selection using Akaike weights, *Psychonomic Bulletin & Review*, 11(1), 192–196. doi.org/10.3758/bf03206482
- Weiner, M.W. *et al.* (2010) The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans, *Alzheimer's & Dementia*, 6(3), 202-211. doi.org/10.1016/j.jalz.2010.03.007
- Weiner, M.W. *et al.* (2017) The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for
  clinical trial improvement, *Alzheimer's & Dementia*, 13(5), 561–571.
  doi.org/10.1016/j.jalz.2016.10.006Wennström, M. *et al.* (2024) 'The Relationship between p-tau217, p-tau231,
  and p-tau205 in the Human Brain Is Affected by the Cellular Environment and Alzheimer's Disease Pathology',
- 663 *Cells*, 13(4), 331. doi: 10.3390/cells13040331
- Wickham, H. (2016) ggplot2: Elegant Graphics for Data Analysis Using the Grammar of Graphics. SpringerVerlag New York. ISBN 978-3-319-24277-4. https://ggplot2.tidyverse.org
- Williams, R. (2012) 'Using the margins command to estimate and interpret adjusted predictions and marginal
  effects', *The Stata Journal*, 12(2), 308–331. doi.org/10.1177/1536867x1201200209
- 668 Xiao, Q. et al. (2022) The Relationship Between Low-Density Lipoprotein Cholesterol and Progression of Mild 669 Cognitive Impairment: The Influence of rs6859 in PVRL2, Front. Genet., 13. doi.org/10.3389/fgene.2022.823406 670
- Yashin, A.I. *et al.* (2018) Hidden heterogeneity in Alzheimer's disease: Insights from genetic association
  studies and other analyses, *Exp Gerontol.* 107, 148–160. doi.org/10.1016/j.exger.2017.10.020
- 673 Yin, M. et al. (2016) Probit Models to Investigate Prevalence of Total Diagnosed and Undiagnosed Diabetes 674 among Aged 45 Years or Older Adults in China, PLoS ONE, 11(10): e0164481. 675 doi.org/10.1371/journal.pone.0164481
- Yong, S.J. *et al.* (2021) The Hippocampal Vulnerability to Herpes Simplex Virus Type I Infection: Relevance
  to Alzheimer's Disease and Memory Impairment, *Front Cell Neurosci*, 15:695738.
  doi.org/10.3389/fncel.2021.695738
- Yu, L. *et al.* (2023) 'Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults', *Acta Neuropathol*, 146(1),1-11. doi: 10.1007/s00401-023-02570-4.
- Zetterberg, H. (2017) 'Review: Tau in biofluids relation to pathology, imaging and clinical features',
   *NeuropatholAppl Neurobiol*, 43(3), 194–199. doi: 10.1111/nan.12378.

- EXAMPLE 2013 Zetterberg, H. and Blennow, K. (2021) 'Moving fluid biomarkers for Alzheimer's disease from research tools
- to routine clinical diagnostics', *Mol Neurodegener*, 16(1),10. doi: 10.1186/s13024-021-00430-x
- Zhang, Z. *et al.* (2016) Causal mediation analysis in the context of clinical research, *Annals of Translational Medicine*, 4(21):425. doi.org/10.21037/atm.2016.11.11
- 687

#### 688 Corresponding Author information

- <sup>\*</sup>Correspondence to ALR and SU, Email address: <u>alr75@duke.edu</u>, <u>Svetlana.Ukraintseva@duke.edu</u>
- 690
- 691
- 692